Konstantin  Konstantinov net worth and biography

Konstantin Konstantinov Biography and Net Worth

Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization.

Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, Calif. for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications.

During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide.

Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

What is Konstantin Konstantinov's net worth?

The estimated net worth of Konstantin Konstantinov is at least $2.77 as of January 20th, 2023. Dr. Konstantinov owns 1,731 shares of Codiak BioSciences stock worth more than $3 as of November 26th. This net worth estimate does not reflect any other assets that Dr. Konstantinov may own. Learn More about Konstantin Konstantinov's net worth.

How old is Konstantin Konstantinov?

Dr. Konstantinov is currently 64 years old. There are 6 older executives and no younger executives at Codiak BioSciences. Learn More on Konstantin Konstantinov's age.

How do I contact Konstantin Konstantinov?

The corporate mailing address for Dr. Konstantinov and other Codiak BioSciences executives is , , . Codiak BioSciences can also be reached via phone at 617-949-4100 and via email at [email protected]. Learn More on Konstantin Konstantinov's contact information.

Has Konstantin Konstantinov been buying or selling shares of Codiak BioSciences?

Konstantin Konstantinov has not been actively trading shares of Codiak BioSciences during the past quarter. Most recently, Konstantin Konstantinov sold 1,069 shares of the business's stock in a transaction on Friday, January 20th. The shares were sold at an average price of $0.58, for a transaction totalling $620.02. Following the completion of the sale, the chief technology officer now directly owns 1,731 shares of the company's stock, valued at $1,003.98. Learn More on Konstantin Konstantinov's trading history.

Who are Codiak BioSciences' active insiders?

Codiak BioSciences' insider roster includes Nicole Barna (Insider), Konstantin Konstantinov (CTO), Sriram Sathyanarayanan (Insider), and Benny Sorensen (Insider). Learn More on Codiak BioSciences' active insiders.

Konstantin Konstantinov Insider Trading History at Codiak BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/20/2023Sell1,069$0.58$620.021,731View SEC Filing Icon  
6/8/2021Sell7,276$25.60$186,265.60View SEC Filing Icon  
See Full Table

Konstantin Konstantinov Buying and Selling Activity at Codiak BioSciences

This chart shows Konstantin Konstantinov's buying and selling at Codiak BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codiak BioSciences Company Overview

Codiak BioSciences logo
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00
Low: $0.05
High: $6.98

Volume

N/A

Average Volume

1,366,845 shs

Market Capitalization

$58,928.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.71